| Budget Amount *help |
¥25,220,000 (Direct Cost: ¥19,400,000、Indirect Cost: ¥5,820,000)
Fiscal Year 2015: ¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2014: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
Fiscal Year 2013: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
|---|
| Outline of Final Research Achievements |
5-hydroxymethylcytosine (5hmC), converted from 5-methylcytosine (5mC) by TET enzymes, is an intermediate of the demethylation pathway. We applied the newly developed oxidative BS (oxBS) treatment to detect 5hmC in blood samples from Kagami-Ogata syndrome (KOS) patients. As a result, it was found that 5hmC was not a major component in abnormally hypermethylated IG-DMR or at a global level, at least in blood from KOS patients. As the brain sample contained large amounts of 5hmC, the neural tissues of KOS patients are promising candidates for analysis in elucidating the role of 5hmC in the neurodevelopmental context.
|
